Merit Medical Systems Inc (OQ:MMSI)
Business Focus: Medical Equipment, Supplies & Distribution
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 1600 West Merit Park Way SOUTH JORDAN UT 84095 |
| Tel: | 1-44-32130509 |
| Website: | https://www.merit.com |
| IR: | See website |
| Key People | ||
| Fred P. Lampropoulos Chairman of the Board, President, Chief Executive Officer | Raul Parra Chief Financial Officer, Treasurer | Neil Peterson Chief Operating Officer |
| Michel J. Voigt Chief Human Resource Officer | Joseph C. Wright Chief Commercial Officer | Brian G. Lloyd Chief Legal Officer, Corporate Secretary |
| Business Overview |
| Merit Medical Systems, Inc. is a manufacturer and marketer of medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Its cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, interventional oncology and spine devices. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. It offers products in five product categories: peripheral intervention, cardiac intervention, custom procedural solutions, original equipment manufacturer (OEM) and endoscopy. |
| Financial Overview |
| For the three months ended 31 March 2023, Merit Medical Systems Inc revenues increased 8% to $297.6M. Net income increased 96% to $20.7M. Revenues reflect Cardiovascular segment increase of 8% to $288M, Endoscopy segment increase of 13% to $9.6M, United States segment increase of 12% to $171.4M, International segment increase of 3% to $126.2M. Net income benefited from Cardiovascular segment income increase of 82% to $23.9M. |
| Employees: | 6,846 as of Dec 31, 2022 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $4,989M as of Mar 31, 2023 |
| Annual revenue (TTM): | $1,173M as of Mar 31, 2023 |
| EBITDA (TTM): | $181.14M as of Mar 31, 2023 |
| Net annual income (TTM): | $84.67M as of Mar 31, 2023 |
| Free cash flow (TTM): | $68.54M as of Mar 31, 2023 |
| Net Debt Last Fiscal Year: | $139.73M as of Mar 31, 2023 |
| Shares outstanding: | 57,493,643 as of Apr 26, 2023 |
| Index Membership: | S&P 600 Small Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2023 INK Research Corp. All rights reserved.
US Quotes Data provided by IEX. US Quotes Data provided by IEX. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.
US Quotes Data provided by IEX. US Quotes Data provided by IEX. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.